AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Pathstone Holdings LLC

Pathstone Holdings LLC grew its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 3.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 347,234 shares of the company's stock after buying an additional 11,703 shares during the period. Pathstone Holdings LLC's holdings in AstraZeneca were worth $27,053,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Stratos Wealth Advisors LLC lifted its stake in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company's stock worth $522,000 after purchasing an additional 133 shares during the period. Bruce G. Allen Investments LLC grew its stake in AstraZeneca by 19.1% during the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company's stock valued at $67,000 after acquiring an additional 138 shares in the last quarter. Carnegie Investment Counsel increased its holdings in shares of AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company's stock worth $1,347,000 after purchasing an additional 138 shares during the last quarter. Crumly & Associates Inc. boosted its position in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company's stock valued at $518,000 after acquiring an additional 143 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company's stock worth $34,000 after buying an additional 146 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on AZN shares. Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Finally, UBS Group raised shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of "Moderate Buy" and a consensus target price of $89.75.

AstraZeneca Trading Down 0.9 %

Shares of AZN stock traded down $0.60 during trading on Wednesday, hitting $63.20. 7,047,699 shares of the stock traded hands, compared to its average volume of 5,303,359. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a market capitalization of $195.96 billion, a P/E ratio of 30.53, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The firm's fifty day moving average price is $74.34 and its 200-day moving average price is $78.06.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.87 EPS. As a group, research analysts forecast that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.